Guobang Pharma (SHSE:605507) EV-to-EBIT : 10.89 (As of Jun. 02, 2025)

Guobang Pharma EV-to-EBIT Chart

Guobang Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBIT	Get a 7-Day Free Trial															9.79	10.97	12.65	10.81	10.91

Competitive Comparison of Guobang Pharma's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Guobang Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guobang Pharma's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Guobang Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Guobang Pharma's EV-to-EBIT falls into.

Guobang Pharma EV-to-EBIT Calculation

Guobang Pharma's EV-to-EBIT for today is calculated as:

Guobang Pharma's current Enterprise Value is ¥10,108 Mil.
Guobang Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥928 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guobang Pharma  (SHSE:605507) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Guobang Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Guobang Pharma's Enterprise Value for the quarter that ended in Mar. 2025 was ¥10,130 Mil.
Guobang Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥928 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guobang Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Guobang Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Guobang Pharma Business Description